Navigation Links
Vilcek Prize for Biomedical Science split between 2 giants of immunology
Date:2/7/2013

me eliminated from the body, and an in-depth analysis of the cellular and molecular basis of autoimmunity. Dr. Flavell is a Fellow of the Royal Society, and a member of the U.S. National Academy of Sciences and the Institute of Medicine.

Dr. Medzhitov has been with Yale University School of Medicine since he emigrated from Russia and joined his former mentor, the late Dr. Charles Janeway, as a postdoctoral fellow. He is a member of the National Academy of Sciences, and received the prestigious Shaw Prize in 2011. Currently, Dr. Medzhitov is exploring three areas of interest: the relationship between inflammation and human diseases; the role of the immune system in allergic reactions; and the social behavior of cells within an organism.

The Vilcek Foundation is also awarding three Vilcek Prizes for Creative Promise in Biomedical Science, recognizing younger immigrant scientists who have demonstrated outstanding achievement. Each prizewinner must not be more than 38 years old, and in a position to lead independent research.

Hashim Al-Hashimi Born in Lebanon, Dr. Al-Hashimi is the J. Lawrence Oncley Collegiate Professor of Chemistry and Biophysics at the University of Michigan. Dr. Al-Hashimi develops methods that combine nuclear magnetic resonance and computational approaches to visualize the dynamics of cellular molecules and processes, such as DNA replication, at an atomic resolution. Analysis of his first target twelve years ago, the HIV RNA molecule, revealed that RNA structures were not static; instead, they morphed into various structures, each with a distinct function. This opened the possibility of RNA-based therapeutic treatments. Currently, Dr. Al-Hashimi characterizes RNA molecules, including HIV RNA, in hopes of identifying small molecules with potential anti-HIV activity. In 2009, he founded the biotechnology company Nymirum, to focus on computational RNA-targeted drug discovery.

Michael Rape Ubiquityla
'/>"/>

Contact: Joyce Li
joyce.li@vilcek.org
212-472-2500
Vilcek Foundation
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. 12th annual Wiley Prize in Biomedical Sciences awarded
2. Wiley Prize in Biomedical Sciences awarded to Rosbash, Hall and Young
3. Israel Prize awarded to Tel Aviv University biochemist
4. Brupbacher Prize goes to cancer researcher Michael Karin
5. 2 climate scientists win 2012 Vetlesen Prize for work on ozone hole, ice cores
6. Leibniz Prizes 2013: DFG honors 11 outstanding researchers
7. VTT wins European innovation prize for a new bio-oil production technique
8. University of Chicagos Graeme Bell receives international diabetes prize
9. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
10. Research gets real - Public votes determine winner of $100,000 research prize
11. CAMH scientist wins Polanyi Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... (Sept. 4, 2008) A variety of organismsfrom ... where the timing and duration of fundamental biological processes ... survive, even under fluctuating environmental conditions. In recent ... molecular basis of these rhythms and how they translate ...
... Breast Cancer Symposium features the latest cutting-edge findings in ... meeting focuses on new and promising therapeutic approaches, as ... breast cancer. To help you take the best ... we encourage you to visit www.sabcs.org to ...
... September 4, 2008) The tumor suppressor gene ... in cases of soft tissue sarcoma (STS), according ... at the Sbarro Institute for Cancer Research and ... Technology at Temple University in Philadelphia, PA, the ...
Cached Biology News:Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2International team reveals first prognosticator of survival in aggressive cancer 2
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... , August 3, 2015 According ... on 3D Cell Culture: Asia ... Market Research, the global 3D cell culture market was valued at ... expand at a CAGR of 29.1% to account for ... Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... a privately,held biotechnology company, announced that it has ... Series D preferred stock offering with its investor,syndicate ... Ventures,L.P., Boston Medical Investors and Silicon Valley Bank ... Chairman of the Board. The Company,expects a second ...
... Application in the ... European Union, ... Food and Drug Administration (FDA) has approved the design of,a single, ... with chemotherapy as first-line,treatment in patients with non-small cell lung cancer ...
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
Cached Biology Technology:Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5Pharmaxis' Aridol Gains First Asian Approval 2
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
LTBP-2 (7B10)...
... Product Rabbit polyclonal to Kv4.2 ... to KLH, corresponding to amino acids 23-43 ... Cross-reacts with Rat.Expected to cross-react with ... identity with immunogen), Rabbit (100% identity with ...
Mouse Anti-Gemin2...
Biology Products: